
Katie was among five indigenous youth leaders across the country who are “leading impactful change within their communities.”
A press release from CNAY recognized the 2025 cohort. CNAT Associate Director of Youth programs Cheyenne Brady-Runsabove said, “the diversity of experience and passion these young leaders exhibit is a true testament to the power of Native youth.”
The CNAY Champions for Change program was started 10 years ago and has more than 50 alumni. Read more about this year’s Champions in the CNAY press release

HILS PhD Student | Advisors: Jodyn E. Platt, MPH, PhD & Francesca A. Williamson, PhD

Health Lab
Michigan Medicine experts discuss CAR T therapy, its use in other clinical trials at U-M and the new Phase I trials that started in March 2025.

Health Lab Podcast
A new national poll on children's health shows that less than half of parents think they have accurate information about bird flu, 2 in 5 parents wish the government was doing more to prevent a bird flu outbreak and only 1 in 3 parents have taken action to protect their family against it. You can read the full article on the Health Lab website.

Department News
Cristina Mitrea, Ph.D., a lecturer IV in DCMB, was recognized by residential students with an "Honor Instructor" award.

The Fundamentals
People with diabetes often have a host of other conditions including cardiovascular disease and kidney disease driven by inflammation. On today's episode, we talk with Dr. Katherine Gallagher, professor of surgery, professor of microbiology and immunology, and the Leland Ira Doan Research Professor of Vascular Surgery at U of M, who is looking at how epigenetics - the influence of environmental factors and behaviors impact on gene expression - might explain changes in the immune system in people with cardiovascular disease, diabetes, and other conditions related to inflammation.
Department News
Karen (Spriggs Lab) successfully defended her thesis, "Deciphering Host-Pathogen Interactions Governing Merkel Cell Polyomavirus (MCPyV) Lifecycle and Disease Pathogenesis,” on March 13, 2025.

Health Lab
Avapritinib, an FDA-approved drug used to treat other types of cancer, also decreases aggressive gliomas in animal models and in an initial cohort of patients with high-grade glioma.